Home > EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA).

(2017) EMCDDA–Europol Joint Report on a new psychoactive substance: N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA). Luxembourg: Joint Reports, Publications Office of the European Union. 19 p.

[img]
Preview
PDF (EMCDDA–Europol Joint Report on a new psychoactive substance) - Published Version
986kB

In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)- 1H-indazole-3-carboxamide, commonly known as AB-CHMINACA, through a joint assessment. The two organisations launched a data collection on this substance for the preparation of a Joint Report as stipulated by Article 5.1 of the Council Decision. The Joint Report was submitted to the Council, the Commission and the European Medicines Agency on 3 July 2017.

Item Type:Evidence resource
Publication Type:Report
Drug Type:New psychoactive substance
Date:11 September 2017
Pages:19 p.
Publisher:Joint Reports, Publications Office of the European Union
Place of Publication:Luxembourg
EndNote:View
Accession Number:HRB (Electronic Only)
Subjects:B Drugs and alcohol substances > New (novel) psychoactive substances
VA Geographic area > Europe

Repository Staff Only: item control page